[Ginkgo extract EGb 761 (tenobin)/HAES versus naftidrofuryl (Dusodril)/HAES. A randomized study of therapy of sudden deafness].
80 patients with idiopathic sudden hearing loss existing no longer than 10 days were included in a randomised reference-controlled study. The therapeutic value of Ginkgo EGb 761 (Tebonin) + HAES was compared to that of Naftidrofuryl (Dusodril)+HAES. The main mechanisms of action of EGb 761 are a vasoregulating activity (increased blood flow), the platelet activating factor antagonism and a prevention of membrane damage caused by free radicals. Naftidrofuryl has antiserotonergic and therefore vasodilatory properties. The statistical analysis of the audiometric data was performed in measuring the relative hearing gain as described by Eibach 1979. After one week of observation, 40% of the patients in each group showed a complete remission of hearing loss. This was also observed by other authors who had compared other drugs. Therefore, in these cases, it is most likely that spontaneous recovery is the most important factor. After two and three weeks of observation, measuring the relative hearing gain, there was a significant borderline benefit of EGb 761 (p = 0.06) without any side effects. Some patients of the reference group developed side effects such as orthostatic dysregulation or headache or sleep disturbances. Minimising side effects should be one of the most important goals in therapy of sudden hearing loss until the efficiency of infusion therapy is proved.
Hoffmann
F
F
Universitäts-HNO-Klinik Freiburg im Breisgau.
Beck
C
C
Schutz
A
A
Offermann
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage* / Q000009:adverse effects; D020441:Ginkgo biloba; D003639:Hearing Loss, Sudden / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000008:administration & dosage* / Q000009:adverse effects; D010936:Plant Extracts; D014012:Tinnitus / Q000188:drug therapy / Q000209:etiology; D000096983:Ginkgo Extract
D005419:Flavonoids; D006895:Hydroxyethyl Starch Derivatives; D009257:Nafronyl; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract